STAT

•

チャンネル • 2個の番組

ビジネス

ビジネス

アップデート：毎週
ニュース

ニュース

アップデート：隔週

6月18日

406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises

This week: New hope for people living with Huntington’s disease, and a report card on RFK Jr.’s effort to remake health in America. The Food and Drug Administration reversed its opposition to a closely watched gene therapy for Huntington’s disease, clearing a path for its maker, the biotech company UniQure, to file for U.S. approval. Joining us to discuss this new development and what it means for the Huntington’s community is Lauren Holder, a Huntington’s disease advocate who is living with the early stages of the disease. A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job as the secretary of the Department of Health and Human Services. He entered the role with a long to-do list, and a goal of delivering measurable improvements within two years. How has he fared? Isabella Cueto, STAT’s chronic disease reporter, has been closely tracking Kennedy and the MAHA movement’s actions, and joins us to discuss.

6月18日

•

36分
1日前

407: The mysterious case of Eli Lilly's obesity drug

Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. We bring on our colleague Lizzy Lawrence to discuss her scoop that Lilly and the Food and Drug Administration have allowed one person to receive the pharma company's obesity candidate, retatrutide, through the FDA’s “compassionate use” program. We also discuss the resurgence of M&A, Lilly's interest in a hair loss drug, and then the FDA's reversal on rare disease drugs.

1日前

•

43分
6月11日

405: An obesity drug deep-dive, and peptides move mainstream

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.[2:37 PM]Undark’s Sara Talpos joins the podcast to discuss her reporting on the peptide BPC-157, and how its jumped from a Croatian lab to bodybuilding forums on Reddit to the FDA. (STAT co-published Talpos articles; the second piece was was supported by the Pulitzer Center). We also discuss the latest news in the life sciences, including obesity data from the American Diabetes Association meeting and a record-breaking IPO.

6月11日

•

36分
6月4日

404: What RevMed's pancreatic cancer drug meant for one patient

Why did oncologists give a standing ovation to a data presentation on Revolution Medicines' pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly this week? And are concrete beaches better than normal beaches? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. We bring on Leanna Stokes, who was diagnosed with metastatic pancreatic cancer in 2023. She discusses how participating in RevMed's trial for daraxonrasib has affected her disease and life, and what the drug means for patients and the field. We also chat about other data presented during last week's meeting of the American Society of Clinical Oncology, the market reaction to Abivax's ulcerative colitis data, and the upcoming meeting of the American Diabetes Association.

6月4日

•

38分
5月28日

403: Biotech exec Jeremy Levin on the industry's strategic turning point

On this week’s episode of “The Readout LOUD,” we chat with longtime biotech executive Jeremy Levin about his new book, “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust.” That sounds alarmist, and it is in some respects, but as Levin explains, the book is also a roadmap to a brighter future for the biotech industry.

5月28日

•

47分
2025/07/24

362: A mother’s perspective on Sarepta’s gene therapy halt

We bring on a mother whose 7-year-old has Duchenne muscular dystrophy, and hear her thoughts on Sarepta’s decision to pull its treatment Elevidys from the market, following a request from the Food and Drug Administration. We also talk about a rare mega-round for a new oncology biotech and an emerging class of drugs aimed at helping people stay awake.

2025/07/24

•

37分
5月21日

402: Guarding biotech from China and big bets in longevity

On this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. They share some of the juicy conversations and insights, including BridgeBio CEO Neil Kumar's comments that the company is publishing “not the right structures” in their research publications. Listeners also will hear Allison's interview with Joe Betts-LaCroix, CEO of the Sam Altman-backed longevity company Retro Biosciences. Retro is preparing for its first clinical data readout and examining just how much impact AI can have in drug development. The hosts also discuss colleague Damian Garde's article on how China is tearing biotech apart and one self-appointed spokesperson’s strategy.

5月21日

•

44分
2018/08/02

Episode 22: Biotech's battle for talent, Sanofi's second act, and climbing Mt. Everest

What juicy perks do biotech startups offer to lure increasingly hard-to-find talent? How does Sanofi plan to make up for lost time in the lucrative field of oncology? And veteran biotech journalist Luke Timmerman talks about what it's like to climb Mt. Everest.

2018/08/02

•

23分
2018/08/09

Episode 23: Congressional insider trading, PETA and fake meat, & doctors vs. fund managers

Can insider trading charges derail political campaigns? Should you trust a fund manager over a doctor? And how many rats would you trade for a cow?

2018/08/09

•

21分
5月14日

401: Makary’s departure and Cassidy’s tenuous Senate seat

This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he is leaving, which of his policies will stick, and what we know about his acting replacement, Kyle Diamantas. Washington correspondent Chelsea Cirruzzo also joins us to discuss a closely tracked Republican Senate primary election this weekend. Bill Cassidy, chair of the Senate health committee, is up against two upstart rivals, including a Trump-backed candidate. The outcome of the primary could have far reaching implications for Trump’s health care agenda.

5月14日

•

41分

Voices from the frontiers of health and medicine